Topical tapinarof, an AhR modulator, and roflumilast, a PDE-4 inhibitor, have exhibited favorable efficacy and safety profiles in extensive phase III trials, and both have been approved by the FDA for the topical treatment of plaque psoriasis in adults and, in the case of roflumilast, in children aged 6 and over. Here, AHR is linked to psoriasis vulgaris.